Drug Database
Back to search

Poland· PL-100427770

Rinvoq

A upadacitinib product containing upadacitinibum, registered in Poland by AbbVie Deutschland GmbH & Co. KG. The same ATC class is registered in 13 of our 19 countries.

ATC L04AF03

Checked against URPL (Poland) on

Informational only — not a medical device.

SOURCE REGISTER · PLURPL (Poland)normalisedRinvoqATCL04AF03REGISTER NO.PL-100427770PACKS LISTED1CHECKEDSeptember 27, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about upadacitinibumAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Upadacitinib is registered in 13 of 19 countries.

Countries holding a registration under ATC L04AF03 (upadacitinib), each read from that country’s own register.

  • This record: Poland, from URPL (Poland)
  • 8 of them publish a price we can compare per daily dose
Search upadacitinib products by name

Upadacitinib · ATC L04AF03

13 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Icelandprice
  • Japan
  • Netherlands
  • Norwayprice
  • Polandprice
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of upadacitinib costs, country by country.

Normalised to the WHO defined daily dose (15 mg), so markets compare like for like.

  • 1 market with a comparable price for this class
  • Public list prices, converted to USD at the rate date shown
Open the full comparison — free accountDrug prices for market access

Upadacitinib · price per daily dose (15 mg)

USD · FX 28 Sept 2026

  • CH Switzerland$32.01
Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

URPL (Poland)
Active substance
Upadacitinibum
Manufacturer
AbbVie Deutschland GmbH & Co. KG
Country
Poland (PL)
ATC code
L04AF03
ATC class
Upadacitinib
Defined daily dose
15 mg, O
Reimbursed
Not published by this register
Source register
URPL (Poland)
Last checked
September 27, 2026

Packs & prices · 1

  • gtin
    08054083020334

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

407 interactions on record for upadacitinib.

Graded by severity as the source publishes them — 337 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan
Check upadacitinib against other medicinesHow interaction checks work

Upadacitinib · interactions on record

407 records

  • 337 severe
  • 63 moderate
  • 7 minor

Most severe, free to view

  • PrednisoloneA07EA01severe
  • HydrocortisoneA07EA02severe
  • PrednisoneA07EA03severe
  • BetamethasoneA07EA04severe
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Upadacitinib in 9 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All upadacitinib products

Authorised across Europe · EMA

The same active substance is authorised in 4 EEA countries. Names it is sold under:

  • United Kingdom (Northern Ireland) · Rinvoq
  • Iceland · Rinvoq
  • Liechtenstein · Rinvoq
  • Norway · Rinvoq

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/556a0dbf-bc7b-4d85-b828-10e23adf1f24
GET /v1/drugs/556a0dbf-bc7b-4d85-b828-10e23adf1f24?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Tabletki o przedłużonym uwalnianiu",
  "source": "urpl",
  "strength": "15 mg",
  "packaging": "08054083020334 ¦ Rpz ¦ EU/1/19/1404/001 ¦ 134666\n28 tabl.\nRpz ¦ EU/1/19/1404/002 ¦ 134667\n30 tabl.\nRpz ¦ EU/1/19/1404/003 ¦ 134668\n84 tabl.\nRpz ¦ EU/1/19/1404/004 ¦ 134669\n90 tabl.\nRpz ¦ EU/1/19/1404/005 ¦ 134670\n98 tabl.",
  "substance": "Upadacitinibum 15 mg",
  "common_name": "Upadacitinibum",
  "pl_product_id": "100427770",
  "pozwolenie_nr": null,
  "auth_procedure": "CEN",
  "authorisation_validity": null
}
API referenceMCP serverPlans

See everything about upadacitinib.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console